Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUCAR-E9D/LUCAR-E9K in R/R B-NHL
NCT07093411Phase 1Recruiting
- Sponsor
- Beijing Gaobo Hospital
- Start
- Aug 2025
- Primary completion
- Aug 2028
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of LUCAR-E9D and LUCAR-E9K in B-cell non-Hodgkin lymphoma, sponsored by Beijing Gaobo Hospital. Primary endpoints: Treatment-emergent Adverse Events at 2 years, Pharmacokinetics in peripheral blood at 2 years and 2 more. Started Aug 2025; status: recruiting.
02
Drugs
LUCAR-E9DLUCAR-E9K
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT07093411.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07093411.